Clinical Trial Update: A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) [Phase 3]

View source ↗

Summary

This clinical trial update reports on a Phase 3 study to evaluate the immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13i) in health…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections
• Streptococcal Infections

Drugs mentioned

• 13-valent Pneumococcal Conjugate Vaccine (PCV13i) (pneumococcal conjugate vaccine, 13-valent)

Snippet

Sponsor: CanSino Biologics Inc. | Conditions: Pneumococcal Infections, Streptococcal Infections | Phase 3 | Status: RECRUITING